AMB ADVANCED THERAPEUTICS

AMB Advanced Therapeutics: Boosting the activity of antibiotics to treat multiresistant hospital infections The growing and spread of drug-resistant pathogens is one of the main threats to public health around the world. The project, led by researcher Xavier Daura of the Biotechnology and Biomedicine Institute of the UAB, has developed a platform for the discovery of antibiotic enhancers and suppressors of microbial resistance. Taking as a target a protein involved in the preservation of the ex... ternal membrane of gram-negative bacteria, the team has already identified five small molecules that improve the antimicrobial activity of colistin on a set of bacterial strains, including resistant strains. Colistin, which is toxic at high doses, was reintroduced in clinical practice as a last resort antibiotic for patients who do not respond to other treatments. However, the number of cases of resistance to colistin is also increasing. The adjuvant candidates identified by AMB Advanced Therapeutics could be used to reduce the dose of colistin and thus reduce the toxicity of the treatment, or enhance its effect.More